SCIENTIFIC PROGRAMME
VIRTUAL FORMAT

THURSDAY, 5TH NOVEMBER 2020

15.00: Satellite Symposium 1

Symposium Bayer

Update and controversies on the treatment of DR and DME

Welcome and Introduction (Chair)
Prof. Rafael Simò (Spain)

Aflibercept: Optimizing Anti-VEGF Therapy in Retinal Disease
Dr. Patricia Udaondo (Spain)

Controversies in DR and DME: Importance of Early, Intensive Treatment
Dr. Olga Simó-Servat (Spain)

EURETINA Guidelines and RWE
Dr. Lluis Arias (Spain)

16.30: Break

17:00 Satellite Symposium 2

Diabetic retinopathy as a biomarker of cardiovascular disease

Symposium Novo Nordisk

Welcome and introduction (Chair)
Prof. Javier Escalada (Spain)

The influence of microangiopathy on macroangiopathy in diabetes
Prof. Didac Mauricio (Spain)

Diabetic retinopathy as a risk factor of cardiovascular disease
Prof. Rafael Simò (Spain)

The role of microangiopathy in heart failure
Prof. Vivencio Barrios (Spain)
FRIDAY, 6th NOVEMBER 2020

09:00 INTRODUCTION AND WELCOME

Prof. Rafael Simó (Spain)

9:10 ORAL COMMUNICATIONS: Basic and translational research in diabetic eye complications

(Supported by Mundipharma)

Chair: Prof. Alan Stitt (UK)

9:12-9:20 Patrice Fort (Michigan, US)
Regional changes of retinal physiology in humans: diabetes vs retinopathy

9:20-9:28 Esmeralda Bosma (Netherlands)
The role of eNOS in VEGF-induced vascular permeability

9:28-9:36 Olga Simó-Servat (Spain)
ERM complex, a therapeutic target for vascular leakage induced by diabetes

9:36-9:44 Hugo Ramos (Spain)
DPP-IV inhibitors for treating early stages of diabetic retinopathy in an experimental model: a dose-efficacy study

9:44-9:52 Tine Van Bergen (Belgium)
Targeting plasma kallikrein with a novel bicyclic peptide inhibitor (THR-149) reduces retinal thickening in a diabetic rat model

9:52-10:00 Eleni Beli (UK)
Diurnal rhythms of myeloid cell infiltration into the retina in type 1 diabetes (T1D)

10:00-10:15 Break

10:15 SESSION: Screening of diabetic retinopathy in Europe: current status and new challenges

Chair: Prof. Peter Scanlon (UK)

10:16-10:24 Katie Hazelgrove (UK)
Incidence of referable diabetic retinopathy at patient’s first screening

10:24-10:32 Jacob Grauslund (Denmark)
Identification and characterization of patients with rapid progression of diabetic retinopathy in the Danish national screening program

10:32-10:40 Deborah M. Broadbent (UK)
Safety, efficacy and cost effectiveness of individual screening for diabetic retinopathy: the Individualised Screening for Diabetic Retinopathy (ISDR) single centre, open label, equivalence randomised controlled trial

10:40-10:48 Rajiv Pandey (Ireland)
Irish National Diabetic Retina Screen programme: 5 rounds of screening and referrals
Use of dilating drops in the Scottish Diabetic Retinopathy Screening Programme

Establishing a diabetic retinopathy screening service in Eswatini

Validation of a deep learning algorithm for diabetic retinopathy

Validation of automated screening for referable diabetic retinopathy with an automatic device (IDxDR) in a Spanish population

11:20-11:30 Break

11:30 SHORT TALK PRESENTATIONS

Experimental research
Chair: Dr. Cristina Hernández (Spain)

Effects of melanocortin receptor agonism in cell models of the inner blood-retinal barrier cultured in diabetic-like conditions

Fluctuating hyperglycaemia has the same effect as sustained hyperglycaemia in an in vitro model of diabetic retinopathy

Anti-inflammatory (m2) response is induced by a synthetic glycolipid-type molecule ((1r)-1-dodecylsulfinyl-5N, 6O-oxomethylenenojirimycin): a new possible treatment in diabetic retinopathy

Involvement of PDGF in neurite outgrowth leading to fibrovascular membranes in PDR

Screening and epidemiology
Chair: Dr. Deborah M. Broadbent

Prevalence of diabetic retinopathy in Greenland

Insights into progression of diabetic retinopathy (DR) severity among primary care patients with diabetes in the United States

The use of virtual clinics to manage diabetic retinopathy patients with delayed follow up appointments in an English hospital eye service

Diabetic eye disease in patients with diabetes mellitus secondary to chronic pancreatitis (DMsCP)
Retinal imaging and artificial intelligence

Chair: Prof. Frank D. Verbraak

12:20 - 12:25 – Rosangela Lattanzio (Italy)
MultiColor imaging to detect different subtypes of retinal microaneurysms in diabetic retinopathy

12:25-12:30 – Andreea Ciudin (Spain)
Retinal sensitivity and gaze fixation: two independent and valuable measurements that could be obtained by using microperimetry

12:30-12:35 – Georgios Bontzos (Greece)
Retinal neurodegeneration, macular circulation and morphology of the foveal avascular zone in diabetic patients. Quantitative cross-sectional study using OCT-A

12:35-12:40 – Mariacristina Parravano (Italy)
Deep capillary plexus impairment as a biomarker of diabetic retinopathy progression in the long-term follow up in type 1 diabetes

Diabetic retinopathy treatment

Chair: Dr. Rosangela Lattanzio

12:45-12:50 – Irene Stratton (UK)
Outcomes in patients with diabetic macular oedema treated with aflibercept for up to three years

12:50-12:55 – Søren Leer Blindbæk (Denmark)
Changes in retinal microvasculature parameters after low-carbohydrate, high-fat diet in type 2 diabetes: a randomized-controlled trial of Danish type 2 diabetic patients

12:55-13:00 – Anna Stage Vergmann (Denmark)
Retinal vascular oxygen saturation in response to panretinal photocoagulation in proliferative diabetic retinopathy: detection of a dose-response relationship?

13:0-13:05 – Diana Minasyan (Ireland)
Evaluation of real-life clinical outcomes of intravitreal anti-VEGF injections for diabetic maculopathy in Diabetic Retina Treatment Unit, Mater Misericordiae University Hospital, Dublin, Ireland

13:10-14:00 LUNCH + POSTER SESSION 1 (See Annex)

14:00 ORAL COMMUNICATIONS: Clinical management and treatment of diabetic eye complications

Chair: Prof. Patrice Fort (USA)

14:00-14:08 Rafael Simó (Spain)
Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease: baseline results of the PRECISED study

14:08-14:16 Kiran Shah (India)
Diabetic retinopathy grade as predictor of outcomes in patients with type 2 diabetes and lower extremity amputations – multicentric longitudinal seven years study
14:16-14:24 José Cunha-Vaz (Portugal)
Ocular and systemic risk markers of diabetic retinopathy progression. A five-year longitudinal study

14:24-14:32 Inês Pereira Marques (Portugal)
Different retinopathy phenotypes in diabetes type 2 show different five-year risks for development of DME and PDR

14:32-14:40 Reinier Schlingemann (Netherlands)
mRNA levels as a biomarker for anti-VEGF response in patients with diabetic macular edema

14:40-14:48 Qian Yang (UK)
Retinal vasculature damage in the deeper plexus is more severe than in the superficial plexus during very early diabetic retinopathy

14:50-15:00 Break

15:00 ROUND TABLE: Looking at retinal neurodegeneration and beyond
(Supported by OM-VIFOR PHARMA)
Chair: Prof. Jakob Grauslund (Denmark)
- The neurovascular unit: a key element in the development of vascular leakage
  Alan Stitt (UK)
- Retinal neurodegeneration in diabetes: clinical and therapeutic implications.
  Rafael Simó (Spain)
- Retinal fingerprint of neurodegenerative diseases
  Frank D. Verbraak (Netherlands)

16:20 SESSION: “Liquid biopsy: usefulness for personalized treatment in DME”
(Supported by ROCHE)
Chair: Dr. Patricia Udaondo (Spain)
- Retinal disease phenotyping through advanced ocular omics
  Andreas Dieckmann (Switzerland)
- Personalized medicine by targeting pro-inflammatory cytokines in DR and DME
  Marina Mesquida (Switzerland)

17:20 SESSION: “What should know the GP about DR?”
(Supported by AstraZeneca)
Chair: Dr. Maria Cristina Parrauso (Italy) and Dr. Xavier Mundet (Spain)
- Relationship with other diabetic complications
  Manel Mata (Spain)
- Can DR influence the management of diabetes?
  Olga Simó-Servat (Spain)

19:30 ANNUAL GENERAL MEETING, PRESENTATION OF NEXT EASDEC MEETING AND FAREWELL

The Board: Rafael Simó (president), Tunde Peto (vice-president), Reinier Schlingemann (treasurer), Stela Vujosevic (secretary), Simon Harding (past-president).

Organizer of the next EASDec meeting: Jakob Grauslund

ANNEX

POSTER SESSION 1 (Screening and epidemiology: 13:15-13:45)

Chair: Tunde Peto (UK)

1 – Steve Aldington (UK)
International students undertaking UK University-validated distance-learning courses in Diabetic Retinopathy Screening (DRS)

2 – Rosalind Creer (UK)
Assessing virtual clinic quality and safety for patients with diabetic eye disease at Manchester Royal Eye Hospital

3 – Iona Minty (UK)
Incidental vascular findings in diabetic eye screening: do patients benefit from referral?

4 – Robert Rehak (UK)
Profile, visual and maculopathy outcomes of patients referred for the first time with pre-proliferative diabetic retinopathy from screening into a hospital eye service

5 – Martina Tomić (Croatia)
Association between homocysteine and the risk of retinopathy in type 2 diabetes

6 – Donal McCullagh (UK)
Audit of referral of patients graded as R3 (proliferative retinopathy) by diabetic eye screening programme Northern Ireland (DESPNI)

7 – Laura Cushley (UK)
Certification of Visual Impairment in Patients with Diabetes Mellitus in Northern Ireland over a 5 year period

8 – Laura Kennelly (Ireland)
Irish Diabetic Retinopathy Screening Programme: An analysis of grade R2 screened patients in 2015

9 – Alan Sproule (UK)
Grading data are only as good as the graders – and all data depends on good quality questions

10 – Tunde Peto (UK)
Young people’s view of Diabetic Retinopathy Screening in Northern Ireland
POSTER SESSION 2 (Retinal imaging and artificial intelligence: 18:15-18:45)

Chair: Simon Harding (UK)

1 – Giuseppe Querques (Italy)  
Nonmydriatic widefield retinal imaging with an automatic white LED confocal imaging system compared with dilated ophthalmoscopy in screening for diabetic retinopathy

2 – Maria Luisa Ribeiro (Portugal)  
Baseline characterization of retinal vascular disease in eyes with mild to moderate non proliferative diabetic retinopathy (NPDR) in diabetes type 2, using novel non-invasive Imaging methods, in a longitudinal, prospective and interventional 2-year clinical study (CORDIS)

3 – Maribel Lopez (Spain)  
Automated diabetic retinopathy quality image assessment: diagnostic accuracy in clinical practice

4 – Lars Díaz (Denmark)  
Neural networks and left/right classification of retinal images

5 – Fethallah Benmansour (Switzerland)  
Machine Learning to Predict Diabetic Retinopathy Improvement in Patients with Mild NPDR Using Systemic and Retinal Imaging Features

6 – Jacob Andersen (Denmark)  
Using Semantic Segmentation for Detection of Microaneurysms in Retinal Images

7 – Thomas Lee Torp (Denmark)  
Validation of the SIVA-plus deep-learning algorithm on retinal vascular calibre in patients with treatment-naïve proliferative diabetic retinopathy before and after panretinal photocoagulation

8 – Kim Gooding (UK)  
Examining the impact of type 2 diabetes on longitudinal changes in fovea thickness

9 – Andrzej Grzybowski (Poland)  
Pilot artificial intelligence based diabetic retinopathy screening programme in Poland

10 – Marie Torm (Denmark)  
Hyperreflective dots on optical coherence tomography scans of diabetic retinopathy – can some of them represent non-perfused capillaries?

11 – Romano Vrabec (Croatia)  
Association between retinal nerve fiber layer, ganglion cell layer with inner plexiform layer and diabetic retinopathy in type 2 diabetes
POSTER SESSION 3 (Diabetic retinopathy treatment 18:55-19:25)

Chair: Reinier Schlingemann (Netherlands)

1 – Valeriya A. Biletskaya (Russia)
Neovascular glaucoma drainage surgery, remote results for diabetic patients.

2 – Eylem Cagiltay (Turkey)
Optical coherence tomography biomarkers to predict anti-VEGF response in diabetic macular edema

3 – Emine Doğan (Turkey)
Short term effects of intravitreal Bevacizumab injection on retinal nerve fiber layer thickness

4 – Mehmet Murat Uzel (Turkey)
Prognostic value of subretinal fluid volume in patients with Ranibizumab-resistant diabetic macular edema treated with intravitreal Dexamethasone

5 – Stela Vujosevic (Italy)
Subthreshold micropulse laser in diabetic macular edema: OCT and OCT-Angiography biomarkers of treatment response

6 – Irina Bashina (Russia)
The use of prolonged corticosteroids for the prevention of macular edema after cataract surgery in patients with diabetes mellitus

7 – Mehmed Uğur Işık (Turkey)
Investigation of choroidal thickness changes after intravitreal Bevacizumab treatment in the treatment of diabetic macular edema

8 – Lazaros Konstantinidis (Switzerland)
Outcomes of hybrid mixed-gauge by bimanual vitrectomy for diabetic tractional retinal detachment

9 – Ernest Lim (UK)
Short-term effectiveness of subthreshold laser therapy for predominantly non-centre involving diabetic macular oedema
MAIN SPONSORS

SPONSORS

SECRETARIAT CONGRESS